Biotechnology
Compare Stocks
2 / 10Stock Comparison
GLPG vs EXEL
Revenue, margins, valuation, and 5-year total return — side by side.
Biotechnology
GLPG vs EXEL — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $1.83B | $11.74B |
| Revenue (TTM) | $1.11B | $2.38B |
| Net Income (TTM) | $321M | $833M |
| Gross Margin | 56.0% | 71.6% |
| Operating Margin | 26.7% | 39.4% |
| Forward P/E | 4.9x | 14.0x |
| Total Debt | $7M | $173M |
| Cash & Equiv. | $88M | $482M |
GLPG vs EXEL — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Galapagos N.V. (GLPG) | 100 | 13.7 | -86.3% |
| Exelixis, Inc. (EXEL) | 100 | 187.0 | +87.0% |
Price return only. Dividends and distributions are not included.
Quick Verdict: GLPG vs EXEL
Each card shows where this stock fits in a portfolio — not just who wins on paper.
GLPG has the current edge in this matchup, primarily because of its strength in income & stability and growth exposure.
- beta 0.74
- Rev growth 303.5%, EPS growth 333.0%, 3Y rev CAGR 66.4%
- Lower volatility, beta 0.74, Low D/E 0.2%, current ratio 20.15x
EXEL is the clearest fit if your priority is long-term compounding.
- 8.3% 10Y total return vs GLPG's -41.9%
- 35.1% margin vs GLPG's 28.9%
- +25.5% vs GLPG's +7.5%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 303.5% revenue growth vs EXEL's 7.0% | |
| Value | Lower P/E (4.9x vs 14.0x) | |
| Quality / Margins | 35.1% margin vs GLPG's 28.9% | |
| Stability / Safety | Beta 0.74 vs EXEL's 0.80, lower leverage | |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | +25.5% vs GLPG's +7.5% | |
| Efficiency (ROA) | 30.5% ROA vs GLPG's 8.3%, ROIC 32.1% vs 12.5% |
GLPG vs EXEL — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
GLPG vs EXEL — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
Income & Cash Flow (Last 12 Months)
EXEL leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
EXEL is the larger business by revenue, generating $2.4B annually — 2.1x GLPG's $1.1B. EXEL is the more profitable business, keeping 35.1% of every revenue dollar as net income compared to GLPG's 28.9%.
| Metric | ||
|---|---|---|
| RevenueTrailing 12 months | $1.1B | $2.4B |
| EBITDAEarnings before interest/tax | $244M | $958M |
| Net IncomeAfter-tax profit | $321M | $833M |
| Free Cash FlowCash after capex | -$266M | $918M |
| Gross MarginGross profit ÷ Revenue | +56.0% | +71.6% |
| Operating MarginEBIT ÷ Revenue | +26.7% | +39.4% |
| Net MarginNet income ÷ Revenue | +28.9% | +35.1% |
| FCF MarginFCF ÷ Revenue | -23.9% | +38.7% |
| Rev. Growth (YoY)Latest quarter vs prior year | +10.9% | +10.0% |
| EPS Growth (YoY)Latest quarter vs prior year | +40.0% | +43.6% |
Valuation Metrics
GLPG leads this category, winning 4 of 4 comparable metrics.
Valuation Metrics
At 4.9x trailing earnings, GLPG trades at a 71% valuation discount to EXEL's 16.6x P/E. On an enterprise value basis, GLPG's 2.8x EV/EBITDA is more attractive than EXEL's 12.7x.
| Metric | ||
|---|---|---|
| Market CapShares × price | $1.8B | $11.7B |
| Enterprise ValueMkt cap + debt − cash | $1.7B | $11.4B |
| Trailing P/EPrice ÷ TTM EPS | 4.87x | 16.62x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 13.96x |
| PEG RatioP/E ÷ EPS growth rate | — | 0.32x |
| EV / EBITDAEnterprise value multiple | 2.75x | 12.68x |
| Price / SalesMarket cap ÷ Revenue | 1.40x | 5.06x |
| Price / BookPrice ÷ Book value/share | 0.48x | 6.03x |
| Price / FCFMarket cap ÷ FCF | — | 13.90x |
Profitability & Efficiency
EXEL leads this category, winning 6 of 8 comparable metrics.
Profitability & Efficiency
EXEL delivers a 40.2% return on equity — every $100 of shareholder capital generates $40 in annual profit, vs $11 for GLPG. GLPG carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to EXEL's 0.08x. On the Piotroski fundamental quality scale (0–9), EXEL scores 7/9 vs GLPG's 6/9, reflecting strong financial health.
| Metric | ||
|---|---|---|
| ROE (TTM)Return on equity | +11.2% | +40.2% |
| ROA (TTM)Return on assets | +8.3% | +30.5% |
| ROICReturn on invested capital | +12.5% | +32.1% |
| ROCEReturn on capital employed | +14.2% | +35.0% |
| Piotroski ScoreFundamental quality 0–9 | 6 | 7 |
| Debt / EquityFinancial leverage | 0.00x | 0.08x |
| Net DebtTotal debt minus cash | -$81M | -$309M |
| Cash & Equiv.Liquid assets | $88M | $482M |
| Total DebtShort + long-term debt | $7M | $173M |
| Interest CoverageEBIT ÷ Interest expense | 11.29x | — |
Total Returns (Dividends Reinvested)
EXEL leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in EXEL five years ago would be worth $18,403 today (with dividends reinvested), compared to $3,695 for GLPG. Over the past 12 months, EXEL leads with a +25.5% total return vs GLPG's +7.5%. The 3-year compound annual growth rate (CAGR) favors EXEL at 34.4% vs GLPG's -12.9% — a key indicator of consistent wealth creation.
| Metric | ||
|---|---|---|
| YTD ReturnYear-to-date | -15.9% | +6.0% |
| 1-Year ReturnPast 12 months | +7.5% | +25.5% |
| 3-Year ReturnCumulative with dividends | -34.0% | +142.8% |
| 5-Year ReturnCumulative with dividends | -63.0% | +84.0% |
| 10-Year ReturnCumulative with dividends | -41.9% | +833.5% |
| CAGR (3Y)Annualised 3-year return | -12.9% | +34.4% |
Risk & Volatility
Evenly matched — GLPG and EXEL each lead in 1 of 2 comparable metrics.
Risk & Volatility
GLPG is the less volatile stock with a 0.74 beta — it tends to amplify market swings less than EXEL's 0.80 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. EXEL currently trades 93.1% from its 52-week high vs GLPG's 73.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.74x | 0.80x |
| 52-Week HighHighest price in past year | $37.78 | $49.62 |
| 52-Week LowLowest price in past year | $24.74 | $33.76 |
| % of 52W HighCurrent price vs 52-week peak | +73.4% | +93.1% |
| RSI (14)Momentum oscillator 0–100 | 46.3 | 67.6 |
| Avg Volume (50D)Average daily shares traded | 165K | 2.7M |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates GLPG as "Hold" and EXEL as "Buy". Consensus price targets imply 19.0% upside for GLPG (target: $33) vs -1.1% for EXEL (target: $46).
| Metric | ||
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Hold | Buy |
| Price TargetConsensus 12-month target | $33.00 | $45.71 |
| # AnalystsCovering analysts | 24 | 32 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +8.1% |
EXEL leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). GLPG leads in 1 (Valuation Metrics). 1 tied.
GLPG vs EXEL: Frequently Asked Questions
10 questions · data-driven answers · updated daily
01Is GLPG or EXEL a better buy right now?
For growth investors, Galapagos N.
V. (GLPG) is the stronger pick with 303. 5% revenue growth year-over-year, versus 7. 0% for Exelixis, Inc. (EXEL). Galapagos N. V. (GLPG) offers the better valuation at 4. 9x trailing P/E, making it the more compelling value choice. Analysts rate Exelixis, Inc. (EXEL) a "Buy" — based on 32 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — GLPG or EXEL?
On trailing P/E, Galapagos N.
V. (GLPG) is the cheapest at 4. 9x versus Exelixis, Inc. at 16. 6x.
03Which is the better long-term investment — GLPG or EXEL?
Over the past 5 years, Exelixis, Inc.
(EXEL) delivered a total return of +84. 0%, compared to -63. 0% for Galapagos N. V. (GLPG). Over 10 years, the gap is even starker: EXEL returned +833. 5% versus GLPG's -41. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — GLPG or EXEL?
By beta (market sensitivity over 5 years), Galapagos N.
V. (GLPG) is the lower-risk stock at 0. 74β versus Exelixis, Inc. 's 0. 80β — meaning EXEL is approximately 8% more volatile than GLPG relative to the S&P 500. On balance sheet safety, Galapagos N. V. (GLPG) carries a lower debt/equity ratio of 0% versus 8% for Exelixis, Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — GLPG or EXEL?
By revenue growth (latest reported year), Galapagos N.
V. (GLPG) is pulling ahead at 303. 5% versus 7. 0% for Exelixis, Inc. (EXEL). On earnings-per-share growth, the picture is similar: Galapagos N. V. grew EPS 333. 0% year-over-year, compared to 58. 0% for Exelixis, Inc.. Over a 3-year CAGR, GLPG leads at 66. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — GLPG or EXEL?
Exelixis, Inc.
(EXEL) is the more profitable company, earning 33. 7% net margin versus 28. 9% for Galapagos N. V. — meaning it keeps 33. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: GLPG leads at 45. 1% versus 37. 6% for EXEL. At the gross margin level — before operating expenses — EXEL leads at 96. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is GLPG or EXEL more undervalued right now?
Analyst consensus price targets imply the most upside for GLPG: 19.
0% to $33. 00.
08Which pays a better dividend — GLPG or EXEL?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
09Is GLPG or EXEL better for a retirement portfolio?
For long-horizon retirement investors, Exelixis, Inc.
(EXEL) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 80), +833. 5% 10Y return). Both have compounded well over 10 years (EXEL: +833. 5%, GLPG: -41. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between GLPG and EXEL?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: GLPG is a small-cap high-growth stock; EXEL is a mid-cap deep-value stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.